2006
DOI: 10.1001/archderm.142.9.1110
|View full text |Cite
|
Sign up to set email alerts
|

Severe Hidradenitis Suppurativa Treated With Adalimumab

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
61
1
2

Year Published

2007
2007
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 70 publications
(65 citation statements)
references
References 12 publications
1
61
1
2
Order By: Relevance
“…A group of 6 patients with recalcitrant severe hidradenitis suppurativa was treated with a subcutaneous dose of 25 mg of etanercept twice a week; after a 24-week treatment, a 61% decrease in the disease’s subjective seriousness index and a 64% improvement of the dermatology life quality index were found [12]. There have also been reported isolated cases of severe hidradenitis suppurativa with good response to adalimumab with 1 subcutaneous dose of 40 mg every 2 weeks [13]. …”
Section: Discussionmentioning
confidence: 99%
“…A group of 6 patients with recalcitrant severe hidradenitis suppurativa was treated with a subcutaneous dose of 25 mg of etanercept twice a week; after a 24-week treatment, a 61% decrease in the disease’s subjective seriousness index and a 64% improvement of the dermatology life quality index were found [12]. There have also been reported isolated cases of severe hidradenitis suppurativa with good response to adalimumab with 1 subcutaneous dose of 40 mg every 2 weeks [13]. …”
Section: Discussionmentioning
confidence: 99%
“…The first reports of the use of adalimumab in HS patients dates from 2006 [73,74]. Initially it showed efficacy in an African American male with concomitant seronegative arthritis [73] and later in a Caucasian male with concomitant inflammatory bowel disease [74].…”
Section: Adalimumabmentioning
confidence: 99%
“…Initially it showed efficacy in an African American male with concomitant seronegative arthritis [73] and later in a Caucasian male with concomitant inflammatory bowel disease [74]. Over the years multiple studies followed, reporting different clinical outcomes.…”
Section: Adalimumabmentioning
confidence: 99%
“…Its addition to therapy with infl iximab was concluded by authors as a prevention of neutralizing antibodies formation and thus prevention of infl iximab effi cacy reduction. Case reports, series of patients and trials studying the effect of etanercept and adalimumab on hidradenitis suppurativa were published (15,16,17,18). The results were comparable with infl iximab -fast improvement of the disease, but often the recurrency occurs soon, even though cases of long-lasting remission without the need of continuous treatment were described.…”
Section: Discussionmentioning
confidence: 97%